rawfin.tv
Sun Pharma's $11.75 Billion Deal Signals Shift from US Generics
MarketsstocksAI Generated

Sun Pharma's $11.75 Billion Deal Signals Shift from US Generics

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Sun Pharma, led by Dilip Shanghvi, has completed its most expensive M&A deal with an $11.75 billion buyout of Organon. This acquisition signals a strategic pivot away from the US generics business, reflecting a changing landscape in the pharmaceutical sector.

SunPharmaM&AGenericsHealthcarePharma

Related Articles

S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

S&P 500 Faces 30% Drop in $20T AI Bust, TS Lombard Warns

stocks
Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

Nasdaq Smashed and Dow Drops as Oil Jumps on Geopolitical Tensions

stocks
Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

Asian Equities Plunge And Bitcoin Retreats As Chinese Markets Enter Bear Territory

stocks
Barclays Workforce Trimmed 5% as Bank Increases Focus on AI

Barclays Workforce Trimmed 5% as Bank Increases Focus on AI

stocks